Optimal (≤1cm) but visible residual disease: Is extensive debulking warranted?
Authors:
- K.C. LongKLK.C. Long
- E.J. TannerETE.J. Tanner
- G.J. GardnerGGG.J. Gardner
- M.M. LeitaoMLM.M. Leitao
- D.A. LevineDLD.A. Levine
- Y. SonodaYSY. Sonoda
- N.R. Abu-RustumNAN.R. Abu-Rustum
- R.R. BarakatRBR.R. Barakat
- D.S. ChiDCD.S. Chi
- 1 August 2013
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 130 (2) , 284-288
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancerGynecologic Oncology, 2012
- Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: Redefining ‘optimal’ residual diseaseGynecologic Oncology, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentumGynecologic Oncology, 2010
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?Gynecologic Oncology, 2006
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002
- Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective StudyGynecologic Oncology, 1998
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992